Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind trial of frexalimab vs teriflunomide in relapsing multiple sclerosis
jRCT2021240004Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of frexalimab in multiple sclerosis (MS) (2 arms), sponsored by Sanofi. Primary endpoint: Annualized relapse rate during the study period. Started Jun 2024; status: active, not recruiting.
02
Drugs
frexalimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on jRCT2021240004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021240004.